Brokerages Set Celcuity Inc. (NASDAQ:CELC) Target Price at $30.80

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $30.80.

Several equities analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Celcuity in a research report on Thursday, May 15th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research note on Monday.

Institutional Trading of Celcuity

Large investors have recently made changes to their positions in the business. Baker BROS. Advisors LP lifted its position in Celcuity by 59.0% during the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock worth $43,046,000 after buying an additional 1,579,182 shares in the last quarter. Paloma Partners Management Co acquired a new position in shares of Celcuity during the first quarter worth approximately $215,000. Tema Etfs LLC bought a new stake in shares of Celcuity during the first quarter valued at approximately $158,000. Trexquant Investment LP grew its stake in shares of Celcuity by 131.3% during the first quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock valued at $272,000 after purchasing an additional 15,280 shares during the last quarter. Finally, EntryPoint Capital LLC increased its holdings in shares of Celcuity by 18.4% in the first quarter. EntryPoint Capital LLC now owns 24,687 shares of the company’s stock valued at $250,000 after purchasing an additional 3,840 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

NASDAQ:CELC opened at $10.60 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The company has a 50-day moving average of $10.17 and a 200-day moving average of $11.60. Celcuity has a 52 week low of $7.58 and a 52 week high of $19.77. The company has a market capitalization of $401.09 million, a price-to-earnings ratio of -4.06 and a beta of 0.56.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.09. As a group, equities research analysts anticipate that Celcuity will post -2.62 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.